According to Company, the patent has profound business implications for Inspira and for its ability to dominate a market with a potential size of $20 billion.
It looks at the rise of fraudulent research and scientists in the life sciences industry, the reasons for the rise, and suggests some measures that companies can take to counter this growing threat to the reputation of the industry and to the safety and security of healthcare delivery.
89% of KLAS-surveyed customers use Xsolis’ AI technology to minimize preventable denials.
Many medical device companies want to go to Japan since it is the third-largest market in the world. Oftentimes, device companies want to register their devices quickly in Japan to be on the market and are not focused enough on the initial medical device reimbursement they will get. This can lead to an unprofitable business if the Japanese reimbursement price is not higher than the sales price in Japan. Are there strategies to increase reimbursement?
Medical Devices must be fully reimbursable – no out of pocket expenses – in Japan. So, how is reimbursement achieved for your medical device?
Black Book’s ad hoc survey of 200 healthcare executives reveals real-time disruptions, cost inflation, and stalled innovation as Trump-era tariffs expand across key healthcare imports.
Industry groups hoping to lessen impacts of Donald Trump’s “Liberation Day” plans on medical products and MedTech development sent letter to the U.S. Trade Representative.
Solventum purification and filtration portfolio expected to be highly complementary with Thermo Fisher’s bioproduction business, strengthening the company in the high growth bioprocessing market.
Teleflex to create a new, independent publicly traded company consisting of its Urology, Acute Care, and OEM businesses. Remaining units and recently announced acquisition expected to remain.
FDA-Cleared Nanotechnology developed by Nanovis is planned for use to enhance Medtronic PEEK interbody fusion devices used in Spine Surgery.